Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
160 hedge funds and large institutions have $980M invested in Adverum Biotechnologies in 2020 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 67 increasing their positions, 38 reducing their positions, and 16 closing their positions.
119% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 16
76% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 38
48% more call options, than puts
Call options by funds: $6.86M | Put options by funds: $4.63M
13% more funds holding
Funds holding: 141 → 160 (+19)
0.69% less ownership
Funds ownership: 100.71% → 100.02% (-0.69%)
42% less capital invested
Capital invested by funds: $1.69B → $980M (-$708M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$32.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.1M |
| 3 |
DM
Deerfield Management
New York
|
+$23.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$22.5M |
| 5 |
O
OrbiMed
New York
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$36.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.4M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$9.81M |
ADVM Hedge Fund Activity: Q3 2020 in Review
160 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2020, worth a combined $980M — down 42% from $1.69B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ADVM positions and 16 closed out — a net gain of 19 holders — while 67 added to existing stakes and 38 trimmed.
The largest buyer was State Street, adding an estimated $32.2M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $36.5M sold.
- 160 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2020, up from 141 in Q2 2020.
- Funds reported $980M of Adverum Biotechnologies stock for Q3 2020, down 42% quarter-over-quarter.
- 35 funds opened new Adverum Biotechnologies positions in Q3 2020 and 16 closed out, a net change of +19 holders.
- The largest Adverum Biotechnologies buyer in Q3 2020 was State Street, an estimated $32.2M added.
- The largest Adverum Biotechnologies seller in Q3 2020 was Acuta Capital Partners, an estimated $36.5M sold.
Based on aggregated 13F filings for Q3 2020.